PDF DatasheetHuman Anti-Topoisomerase II alpha Antibody Product Attributes
Topoisomerase II alpha Previously Observed Antibody Staining Patterns
Observed Subcellular, Organelle Specific Staining Data:
Anti-TOP2A antibody staining is expected to be primarily localized to the nucleus and nucleoli. There is variability in either the signal strength or the localization of signal in nucleoli and nucleus from cell to cell.
Observed Antibody Staining Data By Tissue Type:
Variations in Topoisomerase II alpha antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in hematopoietic cells in the bone marrow, germinal center cells in the lymph node, cells in the seminiferous ducts in testis and germinal center cells in the tonsil. More moderate antibody staining intensity was present in hematopoietic cells in the bone marrow, germinal center cells in the lymph node, cells in the seminiferous ducts in testis and germinal center cells in the tonsil. Low, but measureable presence of Topoisomerase II alpha could be seen inglandular cells in the adrenal gland and breast, respiratory epithelial cells in the bronchus, cells in the endometrial stroma in endometrium, glandular cells in the fallopian tube and gallbladder, pneumocytes in lung, respiratory epithelial cells in the nasopharynx and glandular cells in the parathyroid gland and seminal vesicle. We were unable to detect Topoisomerase II alpha in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of Topoisomerase II alpha expression as measured by anti-Topoisomerase II alpha antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | +++ | ++ | +++ | +++ | ++ | ++ | +++ | ++ | +++ | ++ | ++ | +++ | ++ | ++ | ++ | +++ | ++ | +++ | ++ | +++ |
| TOP2A Variability | ++ | ++ | + | + | ++ | ++ | + | ++ | + | ++ | ++ | ++ | ++ | + | ++ | ++ | ++ | + | + | ++ |
| Topoisomerase II alpha General Information | |
|---|---|
| Alternate Names | |
| DNA topoisomerase 2-alpha, TOP2A | |
| Molecular Weight | |
| 170kDa | |
| Chromosomal Location | |
| 17q21.2 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | TOP2A |
| Entrez Gene ID | 7153 |
| Ensemble Gene ID | ENSG00000131747 |
| RefSeq Protein Accession(s) | XP_005257689, NP_001058, XP_011523467 |
| RefSeq mRNA Accession(s) | XM_005257632, XM_011525165, NM_001067, |
| RefSeq Genomic Accession(s) | NC_018928, NC_000017, NG_027678 |
| UniProt ID(s) | P11388 |
| UniGene ID(s) | P11388 |
| HGNC ID(s) | 11989 |
| Cosmic ID(s) | TOP2A |
| KEGG Gene ID(s) | hsa:7153 |
| PharmGKB ID(s) | PA354 |
| General Description of Topoisomerase II alpha. | |
| This MAb recognizes a 170kDa protein, which is identified as topoisomerase II?. ?? shows no cross-reaction with Topoisomerase II? or I. Topo II? plays important roles in synthesis and transcription of DNA as well as chromosomal segregation during mitosis. It is reported to be a sensitive and specific marker of late S-, G2- ;M-phases in transformed and developmentally regulated normal cells. Topo II? is also implicated in drug resistance of tumor cells. | |
There are no reviews yet.